Specialty contact lenses have a favorable benefit-cost ratio for patients with irregular cornea and ocular surface diseases.

The FDA has accepted for Priority Review the sBLA for aflibercept injection 8mg for the treatment of macular edema following RVO and for monthly dosing in approved indications.

Dementia biomarkers -- phosphorylated tau (P-tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) -- are associated with age, sex, and apolipoprotein E (APOE) ε4 status.

A new drug application has been submitted for Brimochol™ PF (Tenpoint Therapeutics Ltd.) for the treatment of presbyopia.